Evaluation effect of combined detection of CEA,CA125 and CA199 on the efficacy of bevacizumab targeted therapy combined with XELOX adjuvant chemotherapy on patients with advanced colorectal cancer
Objective To evaluate a combined detection of carcinoembryonic antigen(CEA),cancer antigen 125(CA125)and carbohydrate antigen 19-9(CA199)in assessing the efficacy of bevacizumab targeted therapy combined with XELOX(oxaliplatin plus capecitabine)adjuvant chemotherapy on patients with advanced colorectal cancer.Methods A total of 72 patients with advanced colorectal cancer admitted from March 2019 to March 2020 were selected as the subjects of this study,and they were randomly divided into control group(36 cases,XELOX chemotherapy)and experimental group(36 cases,bevacizumab+XELOX chemotherapy)according to the computer random grouping.The clinical efficacy,short-term survival rate,serum index levels and incidence of adverse events were compared between the two groups.Results The clinical control rate in the experimental group was significantly higher than that in the control group(88.89％vs 66.67％,P＜0.05,respectively).The 1-year and 2-year survival rates in the experimental group were 91.67％and 77.78％,respectively,which were significantly higher than those of the control group(P＜0.05).Before treatment,there were no significant differences in serum CEA,CA125 and CA199 levels between the two groups(P＞0.05).After treatment,they were significantly lower in the experimental group than those of the control group(P＜0.05).There was no significant difference in the incidence of adverse events between the two groups(P＞0.05).Conclusion Bevacizumab combined with XELOX adjuvant chemotherapy has an obvious clinical efficacy on patients with advanced colorectal cancer,which can effectively prolong the survival and reduce the levels of serum indicators.The efficacy is reliable and worthy of adoption.
advanced colorectal cancerXELOX(oxaliplatin plus capecitabine)chemotherapybevacizumabcarcinoembryonic antigen(CEA)cancer antigen 125(CA125)carbohydrate antigen 19-9(CA199)
NETL
NSTL
万方数据
维普
